Author: Crawford J, Becker PS, Armitage JO, Blayney DW, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbot M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns J, Pluchino L
Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
Type of cancer: Not disease site specific
Patient population: Adult
Location: International
This is a clinical practice guideline for adults with solid tumours and non-myeloid malignancies who are receiving myelosuppressive chemotherapy. The guideline examines the use of myeloid growth factors (MGFs) in these patients as a method for reducing the incidence of neutropenia. Topics of interest include the benefits and risks of MGFs, as well as their use in prophylactic, therapeutic, and post-transplant settings.
AGREE II - Quality of Reporting Assessment:
Scope and purpose: 63.9%
Applicability: 33.3%
Stakeholder involvement: 44.4%
Editorial independence: 87.5%
Rigour: 67.7%
Clarity presentation: 72.2%
